Autoantibodies following Parvovirus B19 infection

Kerr, Jonathan; Boyd, N. A. M.

doi:10.1016/s0163-4453(96)80008-9

Cited by 43 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In nominally immunocompetent individuals in fection is often asymptomatic, but in affected individuals results most frequently in erythema (especially in children) and arthralgia (particularly in female adults) [55]. This is confirmed by two recent prospective studies performed dur ing epidemic outbreaks, which also showed that aplastic cri sis and intrauterine infection occur at a significant frequen cy [56,57], Furthermore 9 of the total of 96 patients fol lowed up in these two studies exhibited chronic infection with symptoms usually involving arthralgia, hence con firming previous reports of persistent infection in some in dividuals in association with arthritis [58,59], chronic Pathophysiology While a rash-like disease of childhood (fifth disease or erythema infectiosum) has been recognised for many years, it has been difficult to distinguish it clinically from rubella and other childhood rashes. The identification of B19, fol lowing its discovery in 1975 [16], as the causative agent in 1983 [17] allowed further delineation that most cases occur in childhood and result in a mild rash and formation of longlived protective antibody.…”

Section: Introductionmentioning

confidence: 71%

See 1 more Smart Citation

Human Parvovirus B19 and Blood Products

Prowse¹,

Ludlam²,

Yap³

1997

Vox Sanguinis

View full text Add to dashboard Cite

Background and objectives: Human B19 parvovirus (B19), identified in 1975, was only recognised as the causative agent of fifth disease in 1983. The incidence of viraemia is low, around 1 in 1,000, but is sufficient to ensure that most plasma pools for fractionation contain some virus. While infection usually occurs in childhood and is benign, chronic infection sometimes occurs and may be of concern in certain patient groups. Materials and methods: This review is based on a meeting held in March 1995, and addresses recent concerns regarding the potential transmission of B19 infection by pooled plasma products. Results: Recent data on the pathophysiology and assay of this virus are summarised along with possible approaches to donor screening, product screening, and virus removal. Only five cases of symptomatic infection have been reported in persons with haemophilia, but no technology for vims removal is established, and infection may be of concern in pregnant women, and in patients with enhanced red cell turnover or who are immunosuppressed, including those infected with human immunodeficiency vims, but only rarely in immunocompetent patients. Conclusions: For the future, well-validated assays relevant to vims infectivity are required if blood donations, plasma pools, or plasma products are to be screened, and an in-process vims inactivation step for B19 would be highly desirable. In the interim, non-plasma or recombinant products or a selective transfusion policy might be used in patient groups in which B19 infection is of particular concern. Further clinical data on the prognosis and impact of B19 infection are needed to justify both such policies and the future adoption of new technologies designed to reduce any excess B19 infectivity arising from transfused products.

show abstract

Section: Introductionmentioning

confidence: 71%

“…[74,75]. Lastly, some studies indicate an association of B19 infection with the development of a low level autoimmune state, with the development in some individuals of anti-neu trophil as well as the classic anti-self antibodies [56,76].…”

Section: Introductionmentioning

confidence: 99%

Human Parvovirus B19 and Blood Products

Prowse¹,

Ludlam²,

Yap³

1997

Vox Sanguinis

View full text Add to dashboard Cite

show abstract

“…Viral infection may induce increased levels of cytokines such as interferon-Cand tumor necrosis factor-=, that deregulate the phagocytic system, leading to pancytopenia and/or hepatic dysfunction (31). Parvovirus B19 has also been associated with other immunological diseases (32)(33)(34), and the induction of different autoanti-bodies, including antimitochondrial ones, in patients infected with this virus has been reported (35,36).…”

Section: Discussionmentioning

confidence: 99%

Detection of human parvovirus B19 in a patient with hepatitis

Pinho

Alves

Vieira

et al. 2001

Braz J Med Biol Res

View full text Add to dashboard Cite

Parvovirus B19 has been associated by some investigators with cases of severe hepatitis. The aim of the present study was to determine the presence of active parvovirus B19 infection among 129 Brazilian patients with non-A-E hepatitis. The patients were assayed for antibodies against parvovirus B19, IgM class, by ELISA. In IgM-positive cases, parvovirus B19 DNA was assayed by PCR in serum and liver tissue and parvovirus VP1 antigen in liver tissue was assayed by immunohistochemistry. Antibodies against parvovirus B19, IgM class, were detected in 3 (2.3%) of 129 patients with non-A-E hepatitis. Previous surgery and blood transfusions were reported by these 3 patients. One patient was a 56-year-old female with severe hepatitis, with antimitochondrial antibody seropositivity and submassive necrosis at liver biopsy, who responded to corticosteroid therapy. Strong evidence for active parvovirus B19 infection was found in this patient, with parvovirus B19 DNA being detected by PCR in liver tissue. Furthermore, parvovirus VP1 antigen was also detected in liver tissue by immunohistochemistry. The other two IgM-positive patients were chronic hepatitis cases, but active infection was not proven, since neither viral DNA nor antigen were detected in their liver tissues. This and other reports suggest a possible relation between parvovirus B19 infection and some cases of hepatitis.

show abstract

“…Interestingly, after acute infection, serum autoantibodies may be measured in these patients, such as ANAs and rheumatoid factor. 67 This similarity to JIA, in which patients may also have arthritis accompanied by ANA formation, raises the suspicion of a link between parvovirus B19 and JIA. Specific intraocular antibody production has been reported in patients with JIA-associated uveitis.…”

Section: 53mentioning

confidence: 99%

Challenges of Diagnosing Viral Anterior Uveitis

Groen-Hakan

Babu²,

Tuğal-Tutkun

et al. 2017

Ocular Immunology and Inflammation

View full text Add to dashboard Cite

The viral causes of anterior uveitis (AU) emerged with the use of novel molecular diagnostic tests and serologic tests adapted for small volumes (Goldmann-Witmer Coefficient). The viral causes of AU may be underestimated, and some of the presumed idiopathic AU cases will probably be proven to be of viral origin in the coming years. So far, a viral origin of AU was suspected in patients who presented with unilateral hypertensive AU. It is not clear which clinical presentations should raise a suspicion of viral etiology. There is an overlap in the clinical manifestations of AU caused by viruses and other non-viral forms of AU. A viral cause of AU should be suspected in patients with unilateral AU, exhibiting small or medium sized KPs, some form of iris atrophy, high IOP and early development of a cataract and the definitive diagnosis can be proven by aqueous humor analysis.

show abstract

Autoantibodies following Parvovirus B19 infection

Cited by 43 publications

References 18 publications

Human Parvovirus B19 and Blood Products

Human Parvovirus B19 and Blood Products

Detection of human parvovirus B19 in a patient with hepatitis

Challenges of Diagnosing Viral Anterior Uveitis

Contact Info

Product

Resources

About